Search research articles
Contact Us
Filters
Showing results (11-20 of 158) with videos related to
Page
of 16
Sort By:
Current Pharmaceutical Design
|
May 11, 2012
Pathophysiological and clinical aspects of iron chelation therapy in MDS
Norbert Gattermann
Med (New York, N.Y.)
|
March 9, 2024
Imetelstat: Finally a disease-modifying treatment for lower-risk myelodysplastic syndromes?
Fatemeh Majidi, Norbert Gattermann
Cancer
|
July 25, 2007
Valproic acid for the treatment of myeloid malignancies
Andrea Kuendgen, Norbert Gattermann
Best Practice & Research. Clinical Haematology
|
February 11, 2014
When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?
David P Steensma, Norbert Gattermann
Critical Reviews in Oncology/Hematology
|
June 23, 2019
Hematologic improvement with iron chelation therapy in myelodysplastic syndromes: Clinical data, potential mechanisms, and outstanding questions
Heather A Leitch, Norbert Gattermann
Annals of Hematology
|
October 13, 2010
Iron overload in MDS-pathophysiology, diagnosis, and complications
Norbert Gattermann, Eliezer A Rachmilewitz
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
January 13, 2006
Optimized PCR fragments for heteroduplex analysis of the whole human mitochondrial genome with denaturing HPLC
Michael Wulfert, Christoph Tapprich, Norbert Gattermann
Experimental Hematology
|
March 31, 2011
Impaired mitochondrial gene transcription in myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes
Verena Schildgen, Michael Wulfert, Norbert Gattermann
Blood
|
July 19, 2002
New prognostic parameters for chronic myelomonocytic leukemia
Ulrich Germing, Corinna Strupp, Manuel Aivado, et al.
Deutsches Arzteblatt International
|
December 5, 2013
Myelodysplastic syndromes: diagnosis, prognosis, and treatment
Ulrich Germing, Guido Kobbe, Rainer Haas, et al.
Page
of 16
Search research articles
Search
Showing results (11-20 of 158) with videos related to
Sort By:
Page
of 16
Current Pharmaceutical Design
|
May 11, 2012
Pathophysiological and clinical aspects of iron chelation therapy in MDS
Norbert Gattermann
Med (New York, N.Y.)
|
March 9, 2024
Imetelstat: Finally a disease-modifying treatment for lower-risk myelodysplastic syndromes?
Fatemeh Majidi, Norbert Gattermann
Cancer
|
July 25, 2007
Valproic acid for the treatment of myeloid malignancies
Andrea Kuendgen, Norbert Gattermann
Best Practice & Research. Clinical Haematology
|
February 11, 2014
When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?
David P Steensma, Norbert Gattermann
Critical Reviews in Oncology/Hematology
|
June 23, 2019
Hematologic improvement with iron chelation therapy in myelodysplastic syndromes: Clinical data, potential mechanisms, and outstanding questions
Heather A Leitch, Norbert Gattermann
Annals of Hematology
|
October 13, 2010
Iron overload in MDS-pathophysiology, diagnosis, and complications
Norbert Gattermann, Eliezer A Rachmilewitz
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
January 13, 2006
Optimized PCR fragments for heteroduplex analysis of the whole human mitochondrial genome with denaturing HPLC
Michael Wulfert, Christoph Tapprich, Norbert Gattermann
Experimental Hematology
|
March 31, 2011
Impaired mitochondrial gene transcription in myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes
Verena Schildgen, Michael Wulfert, Norbert Gattermann
Blood
|
July 19, 2002
New prognostic parameters for chronic myelomonocytic leukemia
Ulrich Germing, Corinna Strupp, Manuel Aivado, et al.
Deutsches Arzteblatt International
|
December 5, 2013
Myelodysplastic syndromes: diagnosis, prognosis, and treatment
Ulrich Germing, Guido Kobbe, Rainer Haas, et al.
Page
of 16